Buys
Open market- Shares
- +67,669
- Avg price
- $24.97
- Total value
- +$1,689,818
RA CAPITAL MANAGEMENT, L.P. - 10%+ Owner at Hemab Therapeutics Holdings, Inc.
Issuer-level insider activity
- Role
- 10%+ Owner
- Issuer ticker
- COAG on Nasdaq
- Entity type
- Company
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for RA CAPITAL MANAGEMENT, L.P. in Hemab Therapeutics Holdings, Inc.
Sells
Open market- Shares
- Avg price
- Total value
Net
Past year- Shares
- +67,669
- Share %
- 100%
- Total value
- +$1,689,818
Reported holdings for RA CAPITAL MANAGEMENT, L.P. in Hemab Therapeutics Holdings, Inc.
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 6,444,637
- Estimated value
- $160,987,032
- Report date
- 16 Jun 2026
- Price
- $24.98
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 6,444,637
- Estimated value
- $160,987,032
- Report date
- 16 Jun 2026
- Price
- $24.98
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 6,444,637
- Estimated value
- $160,987,032
- Report date
- 16 Jun 2026
- Price
- $24.98
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 6,444,637
- Estimated value
- $160,987,032
- Report date
- 16 Jun 2026
- Price
- $24.98
- Ownership
- Indirect
Form 4 holding
Director
Hemab Therapeutics Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 6,314,525
- Estimated value
- Report date
- 06 May 2026
- Price
- Ownership
- Indirect
Form 4 holding
Director
Hemab Therapeutics Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 6,314,525
- Estimated value
- Report date
- 06 May 2026
- Price
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Hemab Therapeutics Holdings, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Hemab Therapeutics Holdings, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Hemab Therapeutics Holdings, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Hemab Therapeutics Holdings, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Hemab Therapeutics Holdings, Inc.
- Security class
- Series C Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series C Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series C Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series C Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Hemab Therapeutics Holdings, Inc.
- Security class
- Series C Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Hemab Therapeutics Holdings, Inc.
- Security class
- Series C Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Transaction history for RA CAPITAL MANAGEMENT, L.P. in Hemab Therapeutics Holdings, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.